The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
IMMUNOSUPPRESSIVE EFFECTS AND SAFETY OF A SIROLIMUS/CYCLOSPORINE COMBINATION REGIMEN FOR RENAL TRANSPLANTATION1
Abstract
BACKGROUND: Sirolimus, a novel immunosuppressant that inhibits cytokine-driven cell proliferation and maturation, prolongs allograft survival in animal models. After a phase I trial in stable renal transplant recipients documented that cyclosporine and sirolimus have few overlapping toxicities, we conducted an open-label, single-center, phase I/II dose-escalation trial to examine the safety and efficacy of this drug combination. METHODS: Forty mismatched living-donor renal transplant recipients were sequentially assigned to receive escalating initial doses of sirolimus (0.5-7.0 mg/m2/day), in addition to courses of prednisone and a concentration-controlled regimen of cyclosporine. We conducted surveillance for drug-induced side effects among sirolimus-treated patients and compared their incidence of acute rejection episodes as well as mean laboratory values with those of a historical cohort of 65 consecutive, immediately precedent, demographically similar recipients treated with the same concentration-controlled regimen of cyclosporine and tapering doses of prednisone. RESULTS: The addition of sirolimus reduced the overall incidence of acute allograft rejection episodes to 7.5% from 32% in the immediately precedent cyclosporine/prednisone-treated patients. At 18- to 47-month follow-up periods, both treatment groups displayed similar rates of patient and graft survival, as well as morbid complications. Although sirolimus-treated patients displayed comparatively lower platelet and white blood cell counts and higher levels of serum cholesterol and triglycerides, sirolimus did not augment the nephrotoxic or hypertensive proclivities of cyclosporine. The degree of change in the laboratory values was more directly associated with whole blood trough drug concentrations than with doses of sirolimus. CONCLUSIONS: Sirolimus potentiates the immunosuppressive effects of a cyclosporine-based regimen by reducing the rate of acute rejection episodes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116
Solez, K., Axelsen, R. A., Benediktsson, H., Burdick, J. F., Cohen, A. H., Colvin, R. B., Croker, B. P., Droz, D., Dunnill, M. S., Halloran, P. F., et al. (1993) · Kidney International · doi:10.1038/ki.1993.259 · Cited by 1,424
Oates, J. A., Wood, A. J. J., & Kahan, B. D. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912213212507 · Cited by 1,359
Self-citationNourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M.-H., Massague, J., Crabtree, G. R., & Roberts, J. M. (1994) · Nature · doi:10.1038/372570a0 · Cited by 889
Control of p70 S6 kinase by kinase activity of FRAP in vivo
Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Bum Shin, T., & Schreiber, S. L. (1995) · Nature · doi:10.1038/377441a0 · Cited by 705
Webster, J., Marshall, F., Abdalla, M., Dominiczak, A., Edwards, R., Isles, C., Loose, H., Main, J., Padfield, P., Russell, I., et al. (1998) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000599 · Cited by 538
Brahams, D. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90821-x · Cited by 533
Inhibition of the immune response by rapamycin, a new antifungal antibiotic
Martel, R. R., Klicius, J., & Galet, S. (1977) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y77-007 · Cited by 463
RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTING
Calne, R. Y., Lim, S., Samaan, A., Collier, D. S. J., Pollard, S. G., White, D. J. G., & Thiru, S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90417-0 · Cited by 367
Effects of Cyclosporine Therapy on Plasma Lipoprotein Levels
Ballantyne, C. M. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03430010065032 · Cited by 281
Cited by
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Kahan, B. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02480-6 · Cited by 913
Self-citationTan, J., Wu, W., Xu, X., Liao, L., Zheng, F., Messinger, S., Sun, X., Chen, J., Yang, S., Cai, J., et al. (2012) · JAMA · doi:10.1001/jama.2012.316 · Cited by 553
Rapamycin in transplantation: A review of the evidence
Saunders, R. N., Metcalfe, M. S., & Nicholson, M. L. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00460.x · Cited by 461
Sirolimus-tacrolimus combination immunosuppression
McAlister, V. C., Gao, Z., Peltekian, K., Domingues, J., Mahalati, K., & MacDonald, A. S. (2000) · The Lancet · doi:10.1016/s0140-6736(99)03882-9 · Cited by 323
Metadata
- Authors
- Kahan, B. D., Podbielski, J., Napoli, K. L., Katz, S. M., Meier-Kriesche, H.-U., & Van Buren, C. T.
- Venue
- Transplantation
- Published
- 1998-10
- Volume
- 66
- Issue
- 8
- Pages
- 1040-1046
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2115072188
- Cited by
- 288
- References
- 24
- FWCI
- 26.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IMMUNOSUPPRESSIVE EFFECTS AND SAFETY OF A SIROLIMUS/CYCLOSPORINE COMBINATION REGIMEN FOR RENAL TRANSPLANTATION1. https://app.cochat.ai/papers/10.1097/00007890-199810270-00013
- The paper
- Kahan, B. D., Podbielski, J., Napoli, K. L., Katz, S. M., Meier-Kriesche, H.-U., & Van Buren, C. T. (1998). IMMUNOSUPPRESSIVE EFFECTS AND SAFETY OF A SIROLIMUS/CYCLOSPORINE COMBINATION REGIMEN FOR RENAL TRANSPLANTATION1. Transplantation. https://doi.org/10.1097/00007890-199810270-00013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.